Business
New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that four abstracts for Arcutis’ topical roflumilast program in seborrheic dermatitis and psoriasis will be presented at European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually. Specifically, new data from the STRATUM Phase 3 pivotal trial of roflumilast foam in seborrheic dermatitis will be presented in a late-breaking news session. “We are excited that the full results of our STRATUM Phase 3 trial of roflumilast foam in seborrheic dermatitis will be presented orally in a late breaking session, and two additional abstracts on our phase 2 program were accepted as posters. This highlights the large unmet need for novel non-steroidal treatment options for millions of individuals suffering from this condition and the interest from the dermatological community in our investigational therapy,” said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. “We also look forward to sharing the robust safety, efficacy, and tolerability of ZORYVE roflumilast cream in treating sensitive areas, including the face, intertriginous, and genital areas from our phase 3 program in plaque psoriasis.” The oral presentation of the STRATUM Phase 3 pivotal trial of roflumilast foam in seborrheic dermatitis will be presented: D2T01.3: Late breaking news: Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trialPresenting Author: Dr. Andrew BlauveltTime: Friday, Sept 9, 2022, 14.15 - 17.30 pm CEST; 8:15-10:30 am ETRoom: Golden Plenary In addition, the following posters will be electronically available for the entirety of the conference and online through November 30, 2022. Title: Efficacy and safety by race and ethnicity in a randomized, double-blind, vehicle-controlled phase 2a study evaluating once-daily roflumilast foam 0.3% in patients with seborrheic dermatitisePoster P0234Kircik, L et al. Title: Long-term safety and efficacy of roflumilast foam 0.3% in patients with seborrheic dermatitis in a 24-52-week, open-label phase 2 trialePoster P0236Alexis, A et al. Title: Efficacy and tolerability of roflumilast cream 0.3...